Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 601–700 of 2,162
Bajor, D. L., Xu, X., Torigian, D. A., Mick, R., Garcia, L. R., Richman, L. P., Desmarais, C., Nathanson, K. L., Schuchter, L. M., Kalos, M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0154 · Cited by 43
“The agonistic CD28mAb TGN1412 triggered severe cytokine storm in a trial involving healthy volunteers (23).”
BackgroundAb locks for improving the selectivity and safety of antibody drugs
Lin, W.-W., Lu, Y., Chuang, C.-H., & Cheng, T. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00652-z · Cited by 43
UNSPECIFIED (2012) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/jfwe.2012.17.1.401 · Cited by 44
The future of non-human primate use in mAb development
Chapman, K. L., Pullen, N., Andrews, L., & Ragan, I. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.01.002 · Cited by 45
Linker, R. A., & Lee, D.-H. (2009) · Experimental & Translational Stroke Medicine · doi:10.1186/2040-7378-1-5 · Cited by 43
Camperio, C., Muscolini, M., Volpe, E., Mitri, D. D., Mechelli, R., Buscarinu, M. C., Ruggieri, S., Piccolella, E., Salvetti, M., Gasperini, C., et al. (2014) · Immunology Letters · doi:10.1016/j.imlet.2013.12.020 · Cited by 47
The Emerging Role of Pharmacogenomics in Biologics
Lacaná, E., Amur, S., Mummaneni, P., Zhao, H., & Frueh, F. W. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100334 · Cited by 46
“the production of large amounts of inflammatory mediators, which can cause mild to life-threatening inflammatory reactions, as highlighted by a recent example.(3) Tissue necrosis factor (TNF) antagonists block TNF-a from binding to its”
BackgroundCD4 memory T cells on trial: immunological memory without a memory T cell
Bell, E. B., & Westermann, J. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.06.002 · Cited by 44
Off-Target Platelet Activation in Macaques Unique to a Therapeutic Monoclonal Antibody
Santostefano, M. J., Kirchner, J., Vissinga, C. S., Fort, M. M., Lear, S. P., Pan, W., Prince, P. J., Hensley, K. M., Tran, D. T., Rock, D. A., et al. (2012) · Toxicologic Pathology · doi:10.1177/0192623312444029 · Cited by 43
“The underlying causes postulated for infusion reactions include syndromes such as cytokine release (Suntharalingam et al. 2006), anaphylactic (Type IV sensitivity) or anaphylactoid reactions, and antidrug antibody–mediated reactions (Type III hypersensitivity; Winkler et al.”
BackgroundGuilliams, M., Bosschaerts, T., Hérin, M., Hünig, T., Loi, P., Flamand, V., De Baetselier, P., & Beschin, A. (2008) · The Journal of Infectious Diseases · doi:10.1086/590439 · Cited by 43
“of an unexpected cytokine-release syndrome [21, 38], findings in”
BackgroundSam, J., Höfer, T., Kuettel, C., Claus, C., Thom, J. T., Herter, S., Georges, G. J., Korfi, K., Lechmann, M., Eigenmann, M. J., et al. (2024) · Blood · doi:10.1182/blood.2023023381 · Cited by 46
Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells
Dubrot, J., Portero, A., Orive, G., Hernández, R. M., Palazón, A., Rouzaut, A., Perez‐Gracia, J. L., Hervás‐Stubbs, S., Pedraz, J. L., & Melero, I. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0888-z · Cited by 45
“inXammation [4, 5] or systemic inXammatory events [6, 7].”
Current challenges in designing GBM trials for immunotherapy
Weathers, S.-P. S., & Gilbert, M. R. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1716-2 · Cited by 46
“In immunotherapeutics, there is little support for a traditional phase I doseescalation approach on toxicity as toxicity and efficacy are not clearly dose related [46].”
BackgroundArnold, C. R., Pritz, T., Brunner, S., Knabb, C., Salvenmoser, W., Holzwarth, B., Thedieck, K., & Grubeck-Loebenstein, B. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.01.018 · Cited by 42
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model
Weißmüller, S., Kronhart, S., Kreuz, D., Schnierle, B. S., Kalinke, U., Kirberg, J., Hanschmann, K.-M. O., & Waibler, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149093 · Cited by 45
Phillips, P. P. J., Dooley, K. E., Gillespie, S. H., Heinrich, N., Stout, J. E., Nahid, P., Diacon, A. H., Aarnoutse, R. E., Kibiki, G. S., Boeree, M. J., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0597-3 · Cited by 47
“The safety of the participants (often healthy volunteers) is the overwhelming primary concern because incidence and the magnitude of toxicities cannot be readily predicted by preclinical toxicology studies, and unexpected serious adverse events not seen in animal studies do sometimes occur [17].”
BackgroundApplication of lung microphysiological systems to COVID-19 modeling and drug discovery: a review
Sun, A., Hoffman, T., Luu, B. Q., Ashammakhi, N. A., & Li, S. (2021) · Bio-Design and Manufacturing · doi:10.1007/s42242-021-00136-5 · Cited by 45
The promise and perils of immunotherapy
Lesch, S., & Gill, S. I. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004453c · Cited by 48
T-cell co-stimulatory molecules: their role in allergic immune reactions
Kallinich, T., Beier, K. C., Wahn, U., Stock, P., & Hamelmann, E. H. (2007) · European Respiratory Journal · doi:10.1183/09031936.00094306 · Cited by 47
Treatment of Graft-versus-Host Disease with Naturally Occurring T Regulatory Cells
Trzonkowski, P., Dukat-Mazurek, A., Bieniaszewska, M., Marek-Trzonkowska, N. M., Dobyszuk, A., Juścińska, J., Dutka, M., Myśliwska, J. M., & Hellmann, A. R. (2013) · BioDrugs · doi:10.1007/s40259-013-0050-5 · Cited by 42
“This was not as obvious a few years ago, at the time of our first attempts with Tregs, when safety concerns with the Treg-stimulating antibody TGN1412 were reported in humans [71].”
Costimulation Blockade in Kidney Transplantation: An Update
Malvezzi, P., Jouvé, T., & Rostaing, L. P. E. (2016) · Transplantation · doi:10.1097/tp.0000000000001344 · Cited by 47
“After receiving intensive cardiopulmonary support (including dialysis), highdose methylprednisolone, and an anti–IL-2 receptor antagonist antibody, they all survived.(49) The severity of the adverse response to TGN1412 correlates with the level of IL-2 release.”
BackgroundIVIG regulates the survival of human but not mouse neutrophils
Schneider, C., Wicki, S., Graeter, S., Timcheva, T. M., Keller, C. W., Quast, I., Leontyev, D., Djoumerska‐Alexieva, I., Käsermann, F., Jakob, S. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01404-0 · Cited by 46
Ipilimumab (Yervoy) and the TGN1412 catastrophe
Bakács, T., Mehrishi, J. N., & Moss, R. W. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.07.005 · Cited by 48
Animal models of multiple sclerosis
Wekerle, H., & Kurschus, F. (2006) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2006.11.004 · Cited by 7
Kitazawa, Y., Fujino, M., Li, X.-K., Xie, L., Ichimaru, N., Okumi, M., Nonomura, N., Tsujimura, A., Isaka, Y., Kimura, H., et al. (2009) · Cell Transplantation · doi:10.1177/096368970901805-619 · Cited by 41
Wang, X., Morgan, D. M., Wang, G., & Mozier, N. M. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.23343 · Cited by 41
“The ‘‘cytokine storm’’ induced in the clinic by TGN1412 indicated the serious consequences of unexpected mammalian responses in response to a particular biotherapeutic (Suntharalingam et al., 2006).”
BackgroundToward improved in vitro models of human cancer
Ayuso, J. M., Park, K.-Y., Virumbrales-Muñoz, M., & Beebe, D. J. (2021) · APL Bioengineering · doi:10.1063/5.0026857 · Cited by 40
Bartholomaeus, P., Semmler, L. Y., Bukur, T., Boisguerin, V., Römer, P. S., Tabares, P., Chuvpilo, S., Tyrsin, D. Y., Matskevich, A., Hengel, H., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302461 · Cited by 40
Mechanisms and treatment approaches for ACLF
Piano, S. S., Mahmud, N., Caraceni, P., Tonon, M., & Mookerjee, R. P. (2023) · Liver International · doi:10.1111/liv.15733 · Cited by 55
The importance of co‐stimulation in the orchestration of T helper cell differentiation
Coquet, J. M., Rausch, L., & Borst, J. G. (2015) · Immunology and Cell Biology · doi:10.1038/icb.2015.45 · Cited by 47
Goettel, J. A., Biswas, S., Lexmond, W. S., Yeste, A., Passerini, L., Patel, B., Yang, S., Sun, J., Ouahed, J., Shouval, D. S., et al. (2015) · Blood · doi:10.1182/blood-2014-12-618363 · Cited by 46
The intriguing options of multispecific antibody formats for treatment of cancer.
Weidle, U. H., Tiefenthaler, G., Weiss, E. H., Georges, G. J., & Brinkmann, U. (2013) · PubMed · Cited by 46
Chan, K. R., Ong, E. Z., Mok, D. Z., & Ooi, E. E. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1079127 · Cited by 40
“For instance, the Phase I trial of the antiCD28 mAb TGN1412 resulted in immune-mediated cytokine storm and multiorgan failure in healthy volunteers, highlighting the importance of assessing the likelihood of such adverse events [79].”
BackgroundWarwas, K. M., Meyer, M., Gonçalves, M., Moldenhauer, G., Bulbuc, N., Knabe, S., Luckner‐Minden, C., Ziegelmeier, C., Heußel, C. P., Zörnig, I., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719116 · Cited by 53
Moreira, A., Müller, M., Costa, P. F., & Kohl, Y. (2021) · Advanced Biology · doi:10.1002/adbi.202101139 · Cited by 52
Uncertainty and Risk-Taking in Science: Meaning, Measurement and Management
Franzoni, C., & Stephan, P. E. (2021) · Research Policy · doi:10.1016/j.respol.2022.104706 · Cited by 58
“…as an influential NIH review pointed-out in 2004 (Rosenberg, Yang, and Restifo 2004), and several agonist antibodies (e.g., targeting CD28, CD40, or 4-1BB) were found to cause serious adverse effects, which in some cases were life-threating for healthy patients (Suntharalingam et al. 2006).”
BackgroundModeling human immune responses to vaccination in vitro
Morrocchi, E., van Haren, S. D., Palma, P., & Levy, O. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.11.002 · Cited by 44
Erikstrup, C., Kronborg, G., Lohse, N., Ostrowski, S. R., Gerstoft, J., & Ullum, H. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181ca3f7c · Cited by 39
“Similarly, extreme acute lymphopenia was described among humans stimulated by anti-CD28.(23) Simian immunodeficiency virus (SIV)-infected sooty mangabeys is another example.”
BackgroundRegulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
Choi, B. D., Gedeon, P. C., Sanchez-Perez, L. A., et al. (2013) · OncoImmunology · doi:10.4161/onci.26757 · Cited by 39
“First, nonspecific activation of endogenous T cells, such as through global ligation with monoclonal antibodies, has resulted in disastrous autoimmune effects.(2) In addition, the development of tumor antigen specific T cells is laborious, often inconsistent, and further complicated by the need for adoptive transfer o…”
BackgroundA new class of bispecific antibodies to redirect T cells for cancer immunotherapy
Rossi, D. L., Rossi, E. A., Cardillo, T. M., Goldenberg, D. M., & Chang, C. (2013) · mAbs · doi:10.4161/mabs.27385 · Cited by 39
Ketelhuth, D. F. J., & Hansson, G. K. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0167 · Cited by 40
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB
Dudal, S., Hinton, H. J., Giusti, A. M., Bacac, M., Muller, M., Fauti, T., Colombetti, S., Heckel, T., Giroud, N., Klein, C., et al. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000132 · Cited by 39
Costimulation Blockade in Kidney Transplant Recipients
van der Zwan, M., Hesselink, D. A., van den Hoogen, M. W. F., & Baan, C. C. (2019) · Drugs · doi:10.1007/s40265-019-01226-6 · Cited by 41
Application of microphysiological systems in biopharmaceutical research and development
Peterson, N. C., Mahalingaiah, P. K., Fullerton, A., & Di Piazza, M. (2020) · Lab on a Chip · doi:10.1039/c9lc00962k · Cited by 39
Sadremomtaz, A., Al-Dahmani, Z. M., Ruiz-Moreno, A. J., Monti, A., Wang, C., Azad, T., Bell, J. C., Doti, N., Velasco-Velázquez, M. A., de Jong, D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00477 · Cited by 40
Blake, S. J., James, J., Ryan, F. J., Caparros-Martin, J., Eden, G. L., Tee, Y. C., Salamon, J. R., Benson, S. C., Tumes, D. J., Sribnaia, A., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100464 · Cited by 39
Hemoadsorption in the critically ill—Final results of the International CytoSorb Registry
Hawchar, F., Tomescu, D. R., Träger, K., Jóskowiak, D., Kogelmann, K., Soukup, J., Friesecke, S., Jacob, D. A., Gummert, J. F., Faltlhauser, A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274315 · Cited by 46
“This so-called cytokine storm can have serious adverse effects mainly due to the mass release of vasoactive substances that can cause severe vasodilatation and hemodynamic instability, damage the endothelium and the glycocalyx leading to capillary leakage and interstitial fluid accumulation, and potentially impair vit…”
BackgroundA two-signal model for T cell trafficking
Marelli‐Berg, F. M., Okkenhaug, K., & Mirenda, V. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.04.008 · Cited by 44
Self-tolerance in multiple sclerosis
Gonsette, R. E. (2012) · Acta Neurologica Belgica · doi:10.1007/s13760-012-0061-x · Cited by 41
“Well tolerated in animals, its infusion into healthy people in a phase I trial provoked a life-threatening cytokine storm [92].”
BackgroundSignalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation
Parry, R. V., Riley, J. L., & Ward, S. G. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.02.004 · Cited by 43
Self-citationPrimate Models in Organ TransplantationPreprint
Anderson, D. J., & Kirk, A. D. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015503 · Cited by 35
“The use of full monoclonal antibodies directed against CD28 was set back by the disastrous results of the TGN1412 trial, in which an antiCD28 antibody with superagonistic qualities caused life-threatening inflammatory responses in all six human volunteers who received the drug (Suntharalingam et al. 2006).”
BackgroundTransparency for Clinical Trials — The TEST Act
Drazen, J. M. (2012) · New England Journal of Medicine · doi:10.1056/nejme1209433 · Cited by 37
Montgomery, R. A., Griesemer, A. D., Segev, D. L., et al. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.01.035 · Cited by 38
Systemic immunotoxicity reactions induced by adjuvanted vaccines
Batista-Duharte, A., Portuondo, D. L., Pérez, O., & Carlos, I. Z. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.02.033 · Cited by 41
Roghanian, A., Stopforth, R. J., Dahal, L. N., & Cragg, M. S. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mir0917-354r · Cited by 46
Lymphocytic subsets play distinct roles in heart diseases
Wang, J., Duan, Y., Sluijter, J. P. G., & Xiao, J. (2019) · Theranostics · doi:10.7150/thno.33112 · Cited by 42
A Systematic Review of the Efficacy of Preclinical Models of Lung Cancer Drugs
Pan, E., Bogumil, D. D., Cortessis, V. K., Yu, S., & Nieva, J. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00591 · Cited by 39
Metabolic Implications of Immune Checkpoint Proteins in Cancer
Stirling, E. R., Bronson, S. M., Mackert, J. D., Cook, K. L., Triozzi, P. L., & Soto‐Pantoja, D. R. (2022) · Cells · doi:10.3390/cells11010179 · Cited by 41
“experienced a life-threatening systemic release of proinflammatory cytokines, commonly referred to as a cytokine storm [54].”
BackgroundAnticancer Drug-Induced Capillary Leak Syndrome
Izzedine, H., Mathian, A., Amoura, Z., Ng, J. H., & Jhaveri, K. D. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.02.014 · Cited by 42
Pharmacogenetics of Idiosyncratic Adverse Drug Reactions
Pirmohamed, M. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_17 · Cited by 41
“Given the nature of these compounds, their high specificity for biological targets, and potency, there are worries about possible serious adverse effects ‐ this was witnessed dramatically in six healthy volunteers given TGN1412 in the UK ( Suntharalingam et al. 2006 ).”
BackgroundOtz, T., Große-Hovest, L., Hofmann, M., Rammensee, H.-G., & Jung, G. (2009) · Leukemia · doi:10.1038/leu.2008.271 · Cited by 38
Regulatory T Cells are Baby′s Best Friends
Teles, A., Zenclussen, A. C., & Schumacher, A. (2013) · American Journal of Reproductive Immunology · doi:10.1111/aji.12067 · Cited by 41
Zhou, H., & Davis, H. M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.014 · Cited by 38
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial
Horvath, C. J., Andrews, L., Baumann, A., Black, L. E., Blanset, D. L., Cavagnaro, J. A., Hastings, K. L., Hutto, D., MacLachlan, T. K., Milton, M., et al. (2012) · Nature reviews. Immunology · doi:10.1038/nri3192-c1 · Cited by 41
Przybył, Ł., Ibrahim, T., Haase, N., Golić, M., Rugor, J., Luft, F. C., Bendix, I., Serdar, M., Wallukat, G., Staff, A. C., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04892 · Cited by 38
Role of receptor occupancy assays by flow cytometry in drug development
Stewart, J. J., Green, C. L., Jones, N., Liang, M., Xu, Y., Wilkins, D. E. C., Moulard, M., Czechowska, K., Lanham, D., McCloskey, T. W., et al. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21355 · Cited by 38
“1 mg/kg was 20- to 30-fold too high; resulting in life-threatening cytokine release syndrome in the healthy volunteers (32,39,44,45).”
BackgroundRenal regeneration after acute kidney injury
Coelho, S., Cabral, M. G., Lopes, J. A., & Jacinto, A. (2018) · Nephrology · doi:10.1111/nep.13256 · Cited by 43
“Administration of anti-CD28 superagonist antibody was shown to increase Tregs and protect from AKI in a mice model, but phase I studies in healthy volunteers showed unexpected life-threatening adverse effects with this drug.(90,91) Very recently, treatment of mice with a hybrid cytokine (IL-233, that bears the activit…”
BackgroundToker, A., & Ohashi, P. S. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.05.001 · Cited by 41
Chauhan, J., Ravva, M. K., & Sen, S. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b02542 · Cited by 37
Spred-2 Deficiency Exacerbates Lipopolysaccharide-Induced Acute Lung Inflammation in Mice
Xu, Y., Ito, T., Fushimi, S., Takahashi, S., Itakura, J., Kimura, R., Sato, M., Mino, M., Yoshimura, A., & Matsukawa, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108914 · Cited by 52
“LPS induces the rapid production of proinflammatory cytokines and chemokines that can induce ALI in humans [20].”
BackgroundKieburtz, K. D., & Olanow, C. W. (2007) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20006 · Cited by 42
Bühler, P., Molnár, E., Dopfer, E. P., Wolf, P., Gierschner, D., Wetterauer, U., Schamel, W. W. A., & Elsässer‐Beile, U. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181a697eb · Cited by 39
“Understanding the T-cell activation requirements of this diabody is important in the light of a recent report, in which T-cell activating monoclonal antibodies (mAbs) led to a general activation of T-cells with massive side effects.(19) The Copyright r 2009 by Lippincott Williams & Wilkins Received for publication Dec…”
BackgroundResultNada, A., & Somberg, J. C. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31813737dd · Cited by 39
“One issue is the most relevant species used for safety testing of TGN1412.”
BackgroundMethodInfluentialEmanuel, M. B., Rawlins, M. D., Duff, G. W., & Breckenridge, A. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60468-1 · Cited by 36
Hedgecoe, A. M. (2013) · Social Studies of Science · doi:10.1177/0306312713506141 · Cited by 37
“Eventually all six volunteers left the hospital, although one of them, Ryan Wilson, has had all his toes amputated as a result of a form of gangrene, and long-term effects, including cancers and immune-related illnesses, have been predicted (Suntharalingam et al., 2006).”
BackgroundLey, K., Gerdes, N., & Winkels, H. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.308611 · Cited by 37
“storm in healthy volunteers, probably by the activation of tissue memory CD4 T cells.(64) This cytotoxic effect was not”
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
Lichnog, C., Klabunde, S., Becker, E., Fuh, F. K., Tripal, P., Atreya, R. N., Klenske, E., Erickson, R., Chiu, H. H., Reed, C., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00039 · Cited by 40
“A prominent example for this effect is the anti-CD28 antibody TGN1412, which caused a cytokine storm with severe clinical consequences in participants of a phase I study (Suntharalingam et al., 2006).”
BackgroundThe Benefits of Going Small: Nanostructures for Mammalian Cell Transfection
Tay, A. K. P. (2020) · ACS Nano · doi:10.1021/acsnano.0c04624 · Cited by 41
Heck, T. G., Ludwig, M. S., Frizzo, M. N., Rasia‐Filho, A. A., & de Bittencourt, P. I. H. (2020) · Clinical Science · doi:10.1042/cs20200596 · Cited by 40
Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review)
Pintea, I., Petricău, C., Dumitraşcu, D. I., Muntean, A. M., Brănişteanu, D. C., Branisteanu, D. E., & Deleanu, D. M. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10381 · Cited by 47
“digital gangrene to TGN1412 agent, directed against T cell surface CD28, caused by polyclonal activation of T lympho‐ cytes and secondary cytokine storm; aseptic meningitis, capillary permeability syndrome and secondary pulmonary edema, encephalopathy, fever, in the context of muromonab (OK3) administration, a monoclo…”
BackgroundIn Vitro Biomimetic Model of the Human Immune System for Predictive Vaccine Assessments
Drake, D. R., Singh, I., Nguyen, M. N., Kachurin, A., Wittman, V., Parkhill, R., Kachurina, O., Moser, J. M., Burdin, N., Moreau, M., et al. (2012) · Disruptive Science and Technology · doi:10.1089/dst.2012.0006 · Cited by 40
“24 Despite attempts to improve these animal models, such as by engineering humanized mouse strains to contain specific human gene products of interest, they cannot completely replicate the human ge-netic and phenotypic variation that is so important to consider when evaluating human responses.”
Frazier, K. S., Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C., Scicchitano, M. S., Weaver, J. L., & Zabka, T. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623315570340 · Cited by 35
“Probably, the most publicized case of clinical vascular damage due to proinflammatory peptide therapies involved a clinical trial in patients administered the anti-CD28 product TGN1412, and which resulted in effects that were not predicted preclinically (Suntharalingam et al. 2006).”
BackgroundJustice and the Human Development Approach to International Research
London, A. J. (2021) · Oxford University Press eBooks · doi:10.1093/oso/9780197534830.003.0009 · Cited by 36
Karnik, I., Her, Z., Neo, S. H., Liu, W. N., & Chen, Q. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061600 · Cited by 42
“multiorgan failure, and severe depletion of lymphocytes and monocytes, thus having severe life-threatening consequences [13].”
BackgroundNapodano, C., Carnazzo, V., Basile, V., Pocino, K., Stefanile, A., Gallucci, S., Natali, P., Basile, U., & Marino, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316556 · Cited by 43
“…immunotherapies that can trigger a cytokine release storm are T-cell engager antibodies, like the anti-CD19/CD3 antibody blinatumomab [109] and anti-CD28 antibody [110], in which the hyperactivation of T-cells induced by the administered antibodies likely mediates the induction of cytokine release.”
BackgroundSuperagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease
Beyersdorf, N., Ding, X., Hünig, T., & Kerkau, T. (2009) · Blood · doi:10.1182/blood-2009-04-218248 · Cited by 35
Emerging Therapies for Rheumatoid Arthritis
Kalden, J. R. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0032-4 · Cited by 39
“These data contrast markedly with the results obtained when the CD28 superagonistic monoclonal antibody was administered at significantly higher doses to volunteers, with the latter developing a cytokine release syndrome [11, 12].”
ResultAn immunologically relevant rodent model demonstrates safety of therapy using a tumour‐specific IgE
Josephs, D. H., Nakamura, M., Bax, H. J., Dodev, T. S., Muirhead, G., Saul, L., Karagiannis, P., Ilieva, K. M., Crescioli, S., Gazińska, P., et al. (2018) · Allergy · doi:10.1111/all.13455 · Cited by 35
“Preclinical safety assessments for monoclonal antibodies (mAbs), especially novel immunomodulatory agents, attracted regulatory attention following the significant unexpected adverse events observed with an anti-CD28 super-agonist mAb targeting regulatory T cells during its first-in-human (FIH) clinical trial in 2006.…”
BackgroundInfluentialCytokine release syndrome. Reviewing a new entity in the intensive care unit
García‐Roche, A., Lagares, C. D., Élez, E., & Ferrer, R. (2019) · Medicina Intensiva · doi:10.1016/j.medin.2019.01.009 · Cited by 41
“(TGN1412), requiring ICU admission for respiratory distress and renal failure.(20) In recent years, with the appearance of BiTe and cellular therapies, CRS has been increasingly reported.”
BackgroundRunge, S., & Rosshart, S. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702378 · Cited by 41
Blood purification with CytoSorb in critically ill COVID‐19 patients: A case series of 26 patients
Nassiri, A. A., Hakemi, M. S., Miri, M. M., Shahrami, R., Koomleh, A. A., & Sabaghian, T. (2021) · Artificial Organs · doi:10.1111/aor.14024 · Cited by 35
Etiology and Pathogenesis of Adverse Drug Reactions
Hausmann, O. V., Schnyder, B., & Pichler, W. J. (2012) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000335614 · Cited by 47
Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies
Tabrizi, M. A., Funelas, C. B., & Suria, H. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9220-2 · Cited by 36
“The importance of translational challenges encountered during antibody development is highlighted by the severe adverse events experienced in the first-in-human (FIH) clinical trial in healthy subjects receiving the starting dose of TGN1412 (7).”
BackgroundInfluentialAdverse Consequences of Immunostimulation
Ponce, R. A. (2008) · Journal of Immunotoxicology · doi:10.1080/15476910801897920 · Cited by 35
“The recent response of healthy human volunteers to TGN1412 exemplifies the systemic nature and successful therapeutic management of this syndrome (Suntharalingam et al., 2006).”
BackgroundExtracorporeal blood purification for sepsis
Shum, H., Yan, W., & Chan, T. M. (2016) · Hong Kong Medical Journal · doi:10.12809/hkmj164876 · Cited by 36
Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors
Hale, G., Vos, J. D., Davy, A. D., Sandra, K., & Wilkinson, I. (2024) · mAbs · doi:10.1080/19420862.2024.2402701 · Cited by 44
“22,23 Meanwhile, variant antibodies had been developed with Fc regions mutated to reduce binding to Fc gamma receptors and also to C1q.”
Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies
Jia, H., Jiang, L., Shen, X., Ye, H., Li, X., Zhang, L., Hu, Y., Song, D., Jia, H., & Wang, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02397-5 · Cited by 60
“Nevertheless, harnessing CD28 signaling is needed for careful consideration since the first-in-human trial of CD28 agonist mAb TGN1412 led to serious cytokine release syndrome [103].”
Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy
Rajasekaran, K., Riese, M. J., Rao, S., Wang, L. L., Thakar, M. S., Sentman, C. L., & Malarkannan, S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00176 · Cited by 39
A non-conserved amino acid variant regulates differential signalling between human and mouse CD28
Porciello, N., Grazioli, P., Campese, A. F., Kunkl, M., Caristi, S., Mastrogiovanni, M., Muscolini, M., Spadaro, F., Favre, C., Nunès, J. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03385-8 · Cited by 38
Control of Regulatory T Cells by Co-signal Molecules
Wing, J. B., Tay, C., & Sakaguchi, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_7 · Cited by 38
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.